Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3102 in Obese Subjects and in Patients With Type 2 Diabetes

This study will test the safety and tolerability of omarigliptin. It is hypothesized that administration of once-weekly omarigliptin in obese but otherwise healthy participants, and in obese participants with Type 2 diabetes (T2D) will be sufficiently safe and well tolerated to permit continued clinical investigation.

Inclusion Criteria:

• obese (body mass index [BMI] ≥30 kg/m² and ≤40 kg/m²) male participants and female participants of non-childbearing potential
• has been diagnosed with T2D (Panel B)
• is not actively participating in a weight loss program

Exclusion Criteria:

• has a history of clinically-significant disease (other than T2D)
• has a history of cancer
• has estimated creatinine clearance ≤60 mL/min
• is unable to refrain from or anticipates the use of any prescription or non-prescription medication
• consumes excessive amounts of alcohol or caffeine
• has participated in a previous omarigliptin study